Breast cancer resistance
protein (BCRP), an
ATP-binding cassette transporter, confers resistance to a series of anticancer
reagents such as
mitoxantrone,
7-ethyl-10-hydroxycamptothecin, and
topotecan. We reported previously that
estrone and 17beta-estradiol reverse BCRP-mediated multidrug resistance. In the present study, we demonstrate that BCRP exports
estrogen metabolites. First, we generated BCRP-transduced LLC-PK1 (LLC/BCRP) cells, in which exogenous BCRP is expressed in the apical membrane, and investigated transcellular transport of 3H-labeled compounds using cells plated on microporous filter membranes. The basal-to-apical transport (excretion) of
mitoxantrone,
estrone, and 17beta-estradiol was greater in LLC/BCRP cells than in LLC-PK1 cells. Thin-layer chromatography of transported
steroids revealed that the transport of
estrone and 17beta-estradiol was independent of BCRP expression. Alternatively, increased excretion of
estrone sulfate and 17beta-estradiol
sulfate was observed in LLC/BCRP cells. BCRP inhibitors completely inhibited the increased excretion of sulfated
estrogens across the apical membrane. Conversion of
estrogens into their
sulfate conjugates was similar between LLC/BCRP and LLC-PK1 cells, suggesting that the increased excretion of
estrogen sulfates was attributable to BCRP-mediated transport. Next, the uptake of 3H-labeled compounds in membrane vesicles from BCRP-transduced K562 (K562/BCRP) cells was investigated. 3H-labeled
estrone sulfate, but not 3H-labeled
estrone or 17beta-estradiol, was taken up by membrane vesicles from K562/BCRP cells, and this was
ATP-dependent. Additionally, BCRP inhibitors suppressed the transport of
estrone sulfate in membrane vesicles from K562/BCRP cells. These results suggest that BCRP does not transport either free
estrone or 17beta-estradiol but exports
sulfate conjugates of these
estrogens.